Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer

British Journal of Surgery

Volumn 89, Issue 3, 2002, Pages 262-271

  Leonard, D S ^a   Hill, A D K ^a   Kelly, L ^a   Dijkstra, B ^a   McDermott, E ^a   O'Higgins, N J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CARCINOMA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENTIATION; DYSPNEA; FEVER; GENE OVEREXPRESSION; HEADACHE; HUMAN; HYPERTENSION; MEDLINE; MONOTHERAPY; PAIN; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; REVIEW;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; CLINICAL TRIALS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-2; MULTICENTER STUDIES; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0036121971     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1323.2001.02022.x     Document Type: Review

References (84)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. The neu oncogene encodes an epidermal growth factor receptor-related protein
4. Receptor protein-tyrosine kinases and their signal transduction pathways
5. Estrogen-dependent, tamoxifen-resistant, tumorigenic growth of MCF-7 cells transfected with HER2/ neu
6. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
7. HER2 causes transformation and tumourigenesis in NIH 3T3 cells
8. Prognostic importance of c-erbB-2 expression in breast cancer
9. The biology of erbB-2/neu/HER-2 and its role in cancer
10. Estrogen-dependent, tamoxifen-resistant, tumorigenic growth of MCF-7 cells transfected with HER2/ neu
11. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial
12. A metanalysis of the interaction between HER2 and response to endocrine therapy (ET) in metastatic breast cancer (MBC)
13. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
14. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
15. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
16. Correlation of c-erbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
17. Amplification of the c-erbB-2 oncogene in prognosis of breast adenocarcinoma
18. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
19. Prognostic significance of c-erbB2 and estrogen receptor status in human breast cancer
20. The long term prognostic significance of c-erbB-2 in primary breast cancer
21. Expression of HER-2/neu oncoprotein in human breast cancer: A comparison of immunohistochemical and western blot techniques
22. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
23. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer
24. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
25. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer
26. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival
27. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
28. In microdissected ductal carcinoma in situ HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology
29. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
30. Immunohistochemical evaluation of c-erbB2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast
31. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity
32. Differential distribution of erbB-2 and pS2 proteins in ductal carcinoma in situ of the breast
33. Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters
34. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
35. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
36. cerbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without ancillary lymph node metastases
37. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
38. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
39. c-erb-B2 expression and response to treatment in metastatic breast cancer
40. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
41. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
42. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11
43. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
44. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
45. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
46. Analysis of cerbB-2 expression using a panel of 6 commercially available antibodies
47. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
48. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
49. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
50. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study
51. C-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples
52. Overexpression of the c-erbB-2 protein in human breast tumor cell lines
53. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
54. The concordance between the clinical trials assay (CTA) and fluorescence in-situ hybridization (FISH) in the Herceptin pivotal trials
55. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
56. Determination of HER-2/Neu status in breast carcinoma: A comparative analysis of immunohistochemistry and fluoresence in situ hybridization
57. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
58. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
59. HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
60. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
61. HER2 antibody for human cancer therapy
62. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
63. The humanized anti-HER2 antibody rhuMAb HER2 mediates antibody dependent cell mediated cytotoxicity via FcgRIII
64. Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of a humanized anti-HER2 antibody
65. Persistent complement activation on tumor cells in breast cancer
66. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
67. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
68. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
69. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
70. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
71. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
72. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
73. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
74. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
75. First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
76. Final report: Weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): Analysis of efficacy by HER2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluoresence in-situ hybridization (FISH)]
77. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER2
78. Weekly docetaxel (D) and rhumabher2 (H) combination therapy as first- or second-line treatment for metastatic breast cancer (MBC)
79. Phase II trial of weekly docetaxel (Taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer
80. Herceptin and vinorelbine for HER2-positive metastatic breast cancer: A phase II study
81. Phase I trial of recombinant human anti-HER2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors
82. Clinical activity with farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: Relationship with tumour type
83. Effects of ZD1839 (Iressa) a novel EGF receptor tyrosine kinase inhibitor on breast cancer cell proliferation and invasiveness
84. A phase II trial of single-agent Rhumab VEGF (recombinant humanised monoclonal antibody to vascular endothelial growth factor) in patients with relapsed metastatic breast cancer